Rewiring T-cell responses to soluble factors with chimeric antigen receptors

Chimeric antigen receptor (CAR)-expressing T cells targeting surface-bound tumor antigens have yielded promising clinical outcomes, with two CD19 CAR-T cell therapies recently receiving FDA approval for the treatment of B-cell malignancies. The adoption of CARs for the recognition of soluble ligands...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, ZeNan L., Lorenzini, Michael H., Chen, Ximin, Tran, Uyen, Bangayan, Nathanael J., Chen, Yvonne Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035732/
https://www.ncbi.nlm.nih.gov/pubmed/29377003
http://dx.doi.org/10.1038/nchembio.2565

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035732/
https://www.ncbi.nlm.nih.gov/pubmed/29377003
http://dx.doi.org/10.1038/nchembio.2565

Ejemplares similares